Literature DB >> 10572105

Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma.

C A Hanson1, P J Kurtin, J A Katzmann, J D Hoyer, C Y Li, J M Hodnefield, C H Meyers, T M Habermann, T E Witzig.   

Abstract

This study evaluated the contributing roles of flow cytometric immunophenotyping of blood and bone marrow and immunohistochemical paraffin section staining of bone marrow biopsies in the staging of B-cell malignant lymphoma. Flow immunophenotyping was performed on a marrow specimen in 175 cases; a corresponding blood specimen was also immunophenotyped in 135 of these cases. Morphologic marrow involvement by lymphoma was found in 59 cases; flow immunophenotyping identified 54 cases with a monoclonal B-cell process: morphology-positive/flow-positive (n = 49), morphology-positive/flow-negative (n = 10), morphology-negative/flow-positive (n = 5), and morphology-negative/flow-negative (n = 111). The 10 morphology-positive/flow-negative cases included 5 follicular and 5 large-cell lymphomas with minimal marrow involvement. All 5 morphology-negative/flow-positive cases were from patients with large-cell lymphomas and bulky clinical disease. Because the blood contained the same B-cell clone in 2 of 2 morphology-negative/flow-positive cases studied, blood contamination of marrow may account for these findings. Blood flow cytometric immunophenotyping studies were positive in 32 cases; 30 had marrow involvement by morphology and were from patients with follicular, mantle cell, lymphoplasmacytic, small lymphocytic, or marginal zone lymphomas. From our results, we conclude that (1) bone marrow flow cytometric immunophenotyping is not a cost-effective replacement for good morphologic evaluation in lymphoma staging and that (2) a positive peripheral blood flow cytometric immunophenotyping study when performed in low-grade lymphomas correlates with marrow involvement.

Entities:  

Mesh:

Year:  1999        PMID: 10572105

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).

Authors:  Dipti Talaulikar; Jane Esther Dahlstrom; Bruce Shadbolt; Amy Broomfield; Anne McDonald
Journal:  J Histochem Cytochem       Date:  2008-06-23       Impact factor: 2.479

2.  Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.

Authors:  Anne M Tierens; Harald Holte; Abdirashid Warsame; Ida M Ikonomou; Junbai Wang; Wing C Chan; Jan Delabie
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

Review 3.  Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies.

Authors:  Falko Fend; Oliver Bock; Markus Kremer; Katja Specht; Leticia Quintanilla-Martinez
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

4.  Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.

Authors:  Shanique Palmer; Curtis A Hanson; Clive S Zent; Luis F Porrata; Betsy Laplant; Susan M Geyer; Svetomir N Markovic; Timothy G Call; Deborah A Bowen; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2008-04-01       Impact factor: 6.998

5.  If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.

Authors:  Patrizia Mancuso; Angelica Calleri; Pierluigi Antoniotti; Jessica Quarna; Giancarlo Pruneri; Francesco Bertolini
Journal:  BMC Cancer       Date:  2010-11-24       Impact factor: 4.430

6.  Bone marrow flow cytometry in staging of patients with B-cell non-Hodgkin lymphoma.

Authors:  Borahm Kim; Seung-Tae Lee; Hee-Jin Kim; Sun Hee Kim
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

7.  Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).

Authors:  Dipti Talaulikar; Bruce Shadbolt; Jane E Dahlstrom; Anne McDonald
Journal:  J Hematol Oncol       Date:  2009-11-22       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.